methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-hydroxy-benzoate | 1020668-74-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-hydroxy-benzoate
• 英文别名: methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-hydroxybenzoate
• CAS: 1020668-74-9
• 化学式: C₁₅H₁₅N₃O₅
• 分子量: 317.301
• InChiKey: QCOAXUWOCPUZCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-hydroxy-benzoate 、 (2R)-1-[(2-methylpropan-2-yl)oxy]propan-2-ol 在 三苯基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.0h， 生成 methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-[(2S)-1-[(2-methylpropan-2-yl)oxy]propan-2-yl]oxy-benzoate
  参考文献：
  名称：

  WO2008/50117

  摘要：

  公开号：
• 作为产物：
  描述：

  5-chloro-N,N-dimethylpyrazine-2-carboxamide 、 3,5-二羟基苯甲酸甲酯 在 caesium carbonate 、 盐酸 作用下， 以 二甲基亚砜 、 水 为溶剂， 反应 3.0h， 生成 methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-hydroxy-benzoate
  参考文献：
  名称：

  WO2008/50117

  摘要：

  公开号：

文献信息

• Chemical Compounds
  申请人：Martin Nathaniel George

  公开号：US20080318968A1

  公开（公告）日：2008-12-25

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , R 2 , R 3 , n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  本发明涉及一类新的化合物组，其公式为(I)或其盐： 其中R1、R2、R3、n、A和HET-1如规范所述，可能在治疗或预防通过葡萄糖激酶(GLK)介导的疾病或医疗状况，如2型糖尿病中有用。本发明还涉及包括上述化合物的制药组合物，使用上述化合物治疗GLK介导的疾病的方法以及制备公式(I)化合物的方法。
• Heteroarylbenzamide derivatives for use in the treatment of diabetes
  申请人：AstraZeneca AB

  公开号：US07964725B2

  公开（公告）日：2011-06-21

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  本发明涉及一种新型化合物组，其化学式为(I)或其盐：其中R1、R2、R3、n、A和HET-1如说明书所述，可用于治疗或预防通过葡萄糖激酶(GLK)介导的疾病或医疗条件，例如2型糖尿病。本发明还涉及包括所述化合物的制药组合物，使用所述化合物治疗由GLK介导的疾病的治疗方法以及制备化合物(I)的方法。
• HETEROARYL BENZAMIDE DERIVATIVES
  申请人：Martin Nathaniel George

  公开号：US20100173825A1

  公开（公告）日：2010-07-08

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , R 2 , R 3 , n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  该发明涉及一类新型化合物或其盐，其化学式为(I)，其中R1，R2，R3，n，A和HET-1如说明书所述，可用于治疗或预防通过葡萄糖激酶（GLK）介导的疾病或医疗状况，例如2型糖尿病。该发明还涉及包含所述化合物的制药组合物，使用该化合物治疗通过GLK介导的疾病的方法以及制备化合物(I)的方法。
• Heteroaryl benzamide derivatives
  申请人：AstraZeneca AB

  公开号：US07671060B2

  公开（公告）日：2010-03-02

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  该发明涉及一种新的化合物组，其化学式为（I）或其盐： 其中R1，R2，R3，n，A和HET-1如规范所述，可能对通过胰岛素样生长因子（GLK）介导的疾病或医疗状况，如2型糖尿病的治疗或预防有用。该发明还涉及包含所述化合物的制药组合物，使用所述化合物治疗由GLK介导的疾病的方法以及制备化合物（I）的方法。
• Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators
  申请人：AstraZeneca AB

  公开号：EP2272834A1

  公开（公告）日：2011-01-12

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  本发明涉及一组新型的式 (I) 化合物或其盐： 其中 R1、R2、R3、n、A 和 HET-1 如说明书所述，可用于治疗或预防通过葡萄糖激酶（GLK）介导的疾病或病症，如 2 型糖尿病。本发明还涉及包含所述化合物的药物组合物、使用所述化合物治疗由 GLK 介导的疾病的方法以及制备式 (I) 化合物的方法。